A5005710176- Dementia and Cognitive Impairment Research
- Functional Brain Connectivity Studies
- Alzheimer's disease research and treatments
- Health, Environment, Cognitive Aging
- Advanced Neuroimaging Techniques and Applications
- Advanced MRI Techniques and Applications
- Neural and Behavioral Psychology Studies
- Face Recognition and Perception
- Cerebrovascular and Carotid Artery Diseases
- Neurological Disease Mechanisms and Treatments
- Mental Health Research Topics
- Neural dynamics and brain function
- Cardiovascular Health and Disease Prevention
- Memory Processes and Influences
- Optical Imaging and Spectroscopy Techniques
- Tryptophan and brain disorders
- Visual perception and processing mechanisms
- EEG and Brain-Computer Interfaces
- Frailty in Older Adults
- Bioinformatics and Genomic Networks
- Sleep and related disorders
- Sleep and Wakefulness Research
- Neurological Disorders and Treatments
- Cognitive Abilities and Testing
- Traumatic Brain Injury and Neurovascular Disturbances
Johns Hopkins Medicine
2015-2024
Johns Hopkins University
2015-2024
Liechtenstein Institute
2023
Hudson Institute
2023
John Wiley & Sons (United States)
2023
Imperial College London
2019
Florey Institute of Neuroscience and Mental Health
2019
The University of Melbourne
2019
Washington University in St. Louis
2019
University of California, Davis
2019
Objective Our objectives were to characterize the inter‐relation of known dementia‐related neuropathologies in one comprehensive model and quantify extent which accumulation accounts for association between age dementia. Methods We used data from 1,362 autopsied participants three community‐based clinicopathological cohorts: Religious Orders Study, Rush Memory Aging Project, Minority Research Study. estimated a series structural equation models summarizing priori hypothesized...
Background: This study had two goals (1) to evaluate changes in neuropsychological performance among cognitively normal individuals that might precede the onset of clinical symptoms, and (2) examine impact Apolipoprotein E (ApoE) genotype on these changes. Methods: Longitudinal neuropsychological, assessments consensus diagnoses were completed prospectively 268 individuals. The mean duration follow-up was 9.2 years (+/- 3.3). 208 participants remained 60 developed cognitive decline,...
<h3>Importance</h3> Clinical trials testing treatments for Alzheimer disease (AD) are increasingly focused on cognitively normal individuals in the preclinical phase of disease. To optimize observing a treatment effect, such need to enroll likely show cognitive decline over duration trial. <h3>Objective</h3> identify which group shows greatest time based their cerebrospinal fluid biomarker profile. <h3>Design, Setting, and Participants</h3> In this cohort study, participants were classified...
Recent evidence indicates that measures from cerebrospinal fluid, MRI scans and cognitive testing obtained cognitively normal individuals can be used to predict likelihood of progression mild impairment several years later, for groups individuals. However, it remains unclear whether these are useful predicting an individual. The increasing focus on early intervention in clinical trials Alzheimer's disease emphasizes the importance improving ability identify which more likely progress over...
This study evaluated the utility of baseline and longitudinal magnetic resonance imaging (MRI) measures medial temporal lobe brain regions collected when participants were cognitively normal largely in middle age (mean 57 years) to predict time onset clinical symptoms associated with mild cognitive impairment (MCI). Furthermore, we examined whether relationship between MRI symptom was modified by apolipoprotein E (ApoE) genotype level reserve (CR). scans CR obtained at from 245 who had been...
To examine the long-term cognitive trajectories of individuals with normal cognition at baseline and distinct amyloid/tau/neurodegeneration (ATN) profiles.Pooling data across 4 cohort studies, 814 cognitively participants (mean age = 59.6 years) were classified into 8 ATN groups using CSF levels β-amyloid 1-42 as a measure amyloid (A), phosphorylated tau 181 (T), total neurodegeneration (N). Cognitive performance was measured previously validated global factor score Mini-Mental State...
Objective: Several models have been proposed for the evolution of Alzheimer's disease (AD) biomarkers. The aim this study was to identify changepoints in a range biomarkers during preclinical phase AD. Methods: We examined nine measures based on cerebrospinal fluid (CSF), magnetic resonance imaging (MRI) and cognitive testing, obtained from 306 cognitively normal individuals, subset whom subsequently progressed symptomatic A changepoint model used determine which had significant change slope...
This study examined whether cerebrospinal fluid (CSF) baseline levels of the synaptic protein NPTX2 predict time to onset symptoms mild cognitive impairment (MCI), both alone and when accounting for traditional CSF Alzheimer's disease (AD) biomarker levels. Longitudinal were also examined.
Graph theory is increasingly being used to study brain connectivity across the spectrum of Alzheimer's disease (AD), but prior findings have been inconsistent, likely reflecting methodological differences. We systematically investigated how methods graph creation (i.e., type correlation matrix and edge weighting) affect structural network properties group estimated networks based on maps cortical thickness obtained from MRI. Four groups were compared: 126 cognitively normal older adults, 103...
Mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia are preceded by a phase of disease, referred to as 'preclinical AD', during which cognitively normal individuals have evidence AD pathology in the absence clinical impairment. This study examined whether magnetic resonance imaging (MRI) measure cortical thickness brain regions, collectively known 'AD vulnerable' predicted time onset symptoms associated with MCI was similarly predictive symptom within 7 years post baseline...
Recent studies suggest that white matter hyperintensities (WMH) on MRI, which primarily reflect small vessel cerebrovascular disease, may play a role in the evolution of Alzheimer disease (AD). In longitudinal study, we investigated whether WMH promote progression AD pathology, or alter association between pathology and risk from normal cognition to mild cognitive impairment (MCI).Two sets analyses were conducted. The relationship whole brain load, based fluid-attenuated inversion recovery...
The APOE ε4 allele increases the risk of developing Alzheimer's disease, whereas ε2 reduces risk. We examined whether cognitive reserve (CR), as measured by an index consisting education, reading, and vocabulary, modifies these associations. CR was at baseline in 257 cognitively normal individuals (mean age 57.2 years) who have been followed for up to 17 years follow-up = 9.2 years). Cox regression models showed that independently affected progressing from cognition onset clinical symptoms:...
Background For individuals with mild cognitive impairment (MCI) or dementia, elevated brain iron together β-amyloid is associated lower functioning. But this needs further investigation among cognitively normal older adults. Purpose To investigate via quantitative susceptibility mapping (QSM) in MRI and PET how cerebral affects cognition Materials Methods In secondary analysis of a prospective study, adults underwent QSM to measure iron. A majority within 30 days MRI. Multiple linear...
The current 'one size fits all' approach to our cognitive aging population is not adequate close the gap between health span and lifespan. In this review paper, we present a novel model for understanding, preventing, treating age-related impairment (ARCI) based on concepts precision medicine. We will discuss how multiple risk factors can be classified into categories because of their interrelatedness in real life, brain drivers or common mechanisms mediating aging, genetic variants that...
To examine the prospective association between blood biomarkers of immune functioning (i.e., innate activation, adaptive immunity, and inflammation) subsequent cognitive decline clinical progression to mild impairment (MCI) in cognitively normal individuals.The BIOCARD study is an observational cohort N = 191 initially healthy participants (mean age 65.2 years). Blood plasma samples were assayed for markers chronic inflammation (TNFR1, IL-6), immunity (CD25), activation (CD14 CD163)....
To determine whether vascular risk and Alzheimer disease (AD) biomarkers have independent or synergistic effects on cognitive decline is associated with the accumulation of AD pathology as measured by change in over time.At baseline, participants (n = 168) were cognitively normal primarily middle-aged (mean 56.4 years, SD 10.9 years) had both factor status proximal CSF available. Baseline was quantified a composite score reflecting presence absence hypertension, hypercholesterolemia,...